Decoy Therapeutics announces 1-for-12 reverse stock split effective March 6, 2026 to regain Nasdaq compliance

Decoy Therapeutics Inc.

Shares reduced from ~6.38M to ~532,000; authorized shares unchanged at 100M.
Split effective 5:00 p.m. ET on March 6; trading on split-adjusted basis begins March 9.
New CUSIP 79400X602; fractional shares cashed out at closing price on March 6.
Equiniti Trust Company acting as exchange agent; all options and warrants adjusted proportionally.
Stockholders approved reverse split range of 1-for-4 to 1-for-15; Board chose 1-for-12 ratio.

item 3.03 item 5.03 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-092748
form_type: 8-K
ticker: DCOY
cik: 0001615219
company_name: Decoy Therapeutics Inc.
filed_at: 2026-03-05T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.646888+00:00
generated_at: 2026-05-15T19:40:29.859356+00:00
sec_items: ["3.03", "5.03", "8.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-092748
json_url: https://secwatch.observer/filing/0001193125-26-092748.json
markdown_url: https://secwatch.observer/filing/0001193125-26-092748.md
text_url: https://secwatch.observer/filing/0001193125-26-092748.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1615219/000119312526092748/0001193125-26-092748-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1615219/000119312526092748/dcoy-20260305.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-092748

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.